Q32 Bio Inc.(US:QTTB)2025-11-13 12:03Clinical Trial Updates - Enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial was completed, increasing the trial size to 33 patients due to strong patient demand, with topline data readout expected in mid-2026[3] - The Part B trial is designed to evaluate the efficacy of bempikibart, with treatment duration of 36 weeks and follow-up through week 52[3] - Emerging signs of clinical activity are being observed among early-enrolling patients in Part B of the trial[4] - The company initiated an open-label extension (OLE) for eligible patients from Part A to enable longer-term follow-up, with dosing ongoing[4] - The company expects to report topline results from the Part B trial in mid-2026[4] Financial Performance - Cash and cash equivalents were $49.0 million as of September 30, 2025, expected to fund operations into 2027[7] - Research and development expenses decreased to $3.6 million for Q3 2025, down from $14.3 million in Q3 2024, a reduction of 74.9%[7] - General and administrative expenses were $4.0 million for Q3 2025, compared to $4.5 million in Q3 2024, a decrease of 11.1%[7] - Net loss for Q3 2025 was $7.4 million, or $0.60 per share, compared to a net loss of $17.6 million, or $1.46 per share, in Q3 2024[7] - Total operating expenses for Q3 2025 were $7.6 million, down from $18.8 million in Q3 2024, a decrease of 59.7%[14]